Treatment OutcomeTissue DonorsBlood DonorsLiving DonorsDonor SelectionTissue and Organ ProcurementBrain DeathDeathEligibility DeterminationAltruismTissue and Organ HarvestingHistocompatibilityKidney TransplantationTransplantation, HomologousGraft SurvivalPatient SelectionLiver TransplantationCadaverUnrelated DonorsOrgan TransplantationHematopoietic Stem Cell TransplantationHistocompatibility TestingTime FactorsRetrospective StudiesNephrectomyGraft vs Host DiseaseGraft RejectionBone Marrow TransplantationAntineoplastic Combined Chemotherapy ProtocolsSurvival RateDisease-Free SurvivalUrologic NeoplasmsAge FactorsMelphalanSurvival AnalysisCisplatinFeasibility StudiesDrug Administration ScheduleRandomized Controlled Trials as TopicThrombolytic TherapyMulticenter Studies as TopicKaplan-Meier EstimateCombined Modality TherapyFollow-Up StudiesNeoplasm Recurrence, LocalSalvage TherapyAntineoplastic AgentsProspective StudiesPaclitaxelNeoplasm StagingAntineoplastic Agents, PhytogenicRegistriesInfusions, IntravenousClinical Trials as TopicDrug Therapy, CombinationAntimetabolites, AntineoplasticDeoxycytidinePrednisoneFibrinolytic AgentsMultiple MyelomaLung NeoplasmsCohort StudiesResearch DesignDoxorubicinPilot ProjectsRecurrenceVincristineNeutropeniaRemission InductionStrokeDisease ProgressionFluorouracilUnited StatesRisk FactorsProportional Hazards ModelsCyclophosphamideDouble-Blind MethodChemotherapy, AdjuvantBreast NeoplasmsMyocardial InfarctionMultivariate AnalysisCarcinoma, Non-Small-Cell LungInsemination, Artificial, HeterologousOocyte Donation